Value
6.6/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 3.0 |
| Analyst target | 9.0 |
AQST · Why this verdict
Why Aquestive Therapeutics (AQST) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue growth is strong, up roughly 66% year-over-year, positioning the company as an industry growth leader. Growth breakdown | Revenue growth should remain a standout versus peers over the next 12 months to sustain the growth-leadership position. | →Stable |
| CounterRapid growth for a specialty pharma name can be driven by a small number of product launches or licensing deals that may not repeat, making the pace difficult to sustain. | ||
The overall risk assessment sits below the minimum floor required for a position, driven in part by cash burn running at roughly 51% of revenue. Bear case | The cash burn rate relative to revenue should narrow meaningfully over the next 12 months as the business scales. | →Stable |
| CounterContinued heavy cash burn for a specialty pharmaceutical company still commercializing products is common and may not resolve quickly even if the underlying growth story remains intact. | ||
The chart has triggered a death cross, a hard technical block in the engine's framework, with momentum failing the minimum bar and the moving-average slope flat. Engine gate (failed) | The death cross should resolve over the next 12 months, with the stock reclaiming its key moving averages and momentum recovering. | →Stable |
| CounterA death cross combined with falling on-balance volume frequently marks the start of an extended downtrend rather than a quick reversal. | ||
Positioning skews bearish, with short interest near 12% of float and a put/call ratio of 2.00, reflecting meaningful defensive or bearish sentiment in the options market. Key risks | Short interest and the put/call ratio should decline toward more neutral levels over the next 12 months if sentiment improves. | →Stable |
| CounterElevated short interest combined with strong revenue growth could set up a short-covering rally if upcoming results continue to beat expectations. | ||
Analyst price targets imply substantial upside of roughly 113% from current levels, even though coverage is light. Sentiment breakdown | Analyst targets should hold or increase further over the next 12 months as more coverage validates the upside case. | →Stable |
| CounterLight analyst coverage means the large implied upside rests on a small number of estimates and could be cut sharply on a single negative update, especially given the death-cross technical setup. | ||
Revenue growth is strong, up roughly 66% year-over-year, positioning the company as an industry growth leader.
→StableGrowth breakdown
- Expectation
- Revenue growth should remain a standout versus peers over the next 12 months to sustain the growth-leadership position.
CounterRapid growth for a specialty pharma name can be driven by a small number of product launches or licensing deals that may not repeat, making the pace difficult to sustain.
The overall risk assessment sits below the minimum floor required for a position, driven in part by cash burn running at roughly 51% of revenue.
→StableBear case
- Expectation
- The cash burn rate relative to revenue should narrow meaningfully over the next 12 months as the business scales.
CounterContinued heavy cash burn for a specialty pharmaceutical company still commercializing products is common and may not resolve quickly even if the underlying growth story remains intact.
The chart has triggered a death cross, a hard technical block in the engine's framework, with momentum failing the minimum bar and the moving-average slope flat.
→StableEngine gate (failed)
- Expectation
- The death cross should resolve over the next 12 months, with the stock reclaiming its key moving averages and momentum recovering.
CounterA death cross combined with falling on-balance volume frequently marks the start of an extended downtrend rather than a quick reversal.
Positioning skews bearish, with short interest near 12% of float and a put/call ratio of 2.00, reflecting meaningful defensive or bearish sentiment in the options market.
→StableKey risks
- Expectation
- Short interest and the put/call ratio should decline toward more neutral levels over the next 12 months if sentiment improves.
CounterElevated short interest combined with strong revenue growth could set up a short-covering rally if upcoming results continue to beat expectations.
Analyst price targets imply substantial upside of roughly 113% from current levels, even though coverage is light.
→StableSentiment breakdown
- Expectation
- Analyst targets should hold or increase further over the next 12 months as more coverage validates the upside case.
CounterLight analyst coverage means the large implied upside rests on a small number of estimates and could be cut sharply on a single negative update, especially given the death-cross technical setup.
TrendMatrix Research · core thesis
Engine thesis — one sentence
AQST shows strong revenue growth and substantial analyst-implied upside, but a death-cross technical breakdown, continued cash burn, and elevated short and options positioning point to significant near-term risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 8.7 |
| Op margin | 0.0 |
| Current ratio | 8.9 |
| FCF quality | 0.0 |
| Moat | 7.0 |
| Piotroski F | 5.6 |
- ▸Cash-burning: FCF -51% of revenue
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 66% YoY
Momentum
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 3.4 |
| OBV | 4.7 |
| MA position | 3.5 |
| Volume | 0.3 |
- ▸Below 200-MA, MA slope flat
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 106%
Insider
5.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
- ▸Modest insider selling — $264,816 (0.050% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.5 |
| quality rank | 0.0 |
| growth rank | 9.3 |
- ▸Industry growth leader
Technical
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.4 |
| support resistance | 6.6 |
| 52w position | 1.4 |
| gap | 6.0 |
Risk (lower is worse)
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.8 |
| days to cover | 0.8 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 1.2 |
| max pain risk | 3.0 |
| beta | 5.2 |
- ▸High IV: 73%
- ▸Above max pain $1
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
How the verdict was assembled
Engine trigger
Mixed signals. Hold existing position.
Engine technical detail
verdict_path:
L4:PATH_F_HOLD_DEFAULTPassed (7)
- ASYMMETRY:6.7>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:35d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.3<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (0)
none
Reward-to-Risk
6.65
Upside
+79.4%
Downside
11.9%
Sizing output
AVOID
SetupRange Bound — RSI 51 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -43% (>40% off 52w high)
Investment implication
The default F-path HOLD fired without any positive-conviction gate triggering — no momentum acceleration, no quality+value crossover, no setup recognition. Highest-clear gate: ASYMMETRY:6.7>=1.5. Top dim: Growth at 10.0; weakest: Momentum at 3.3. The engine's read is one of pattern absence — no directional conviction in either direction at current asymmetry.
The strongest dimensions are Growth at 10.0, Sentiment at 7.8, and Value at 6.6; the weakest are Momentum at 3.3, Risk (lower is worse) at 3.4, and Peer rank at 3.7. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 6.65 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Revenue Growth
Trip ifRevenue growth decelerates below 20% YoY.
- P2Cash Burn Below Risk Floor
Trip ifFree cash flow narrows to above -20% of revenue.
- P3Death Cross Technical Breakdown
Trip ifMomentum score rises above 6.0 from the current 2.4.
- P4Elevated Bearish Positioning
Trip ifShort interest falls below 6% of float.
- P5Large Analyst Implied Upside
Trip ifAverage analyst price target falls by more than 40% from current levels.